Current studies regarding the efficacy of the herb St. John's wort (SJW) in treating mild to moderate cases of depression show conflicting evidence. In this article, we review the literature and consider similarities and differences between studies showing some efficacy and those showing none. Twelve published reports were reviewed. The majority of studies indicated the efficacy of SJW in the treatment of mild to moderate cases of depression. Most trials have had small sample sizes and either a placebo group or a standard pharmaceutical group. Two studies (both pediatric) were uncontrolled. Studies generally reported outcomes that had positive implications for their financial supporters and/or those with whom the primary investigators had acknowledged financial affiliations. More studies that have larger sample sizes and include placebo and pharmaceutical control groups are needed.
as St. John's wort (SJW) . SJW has been used to treat the symptoms of depression by herbalists for centuries (Hobbs, 1997) .
The founding of the NCCAM by the United States Congress in 1998 has resulted in more attention being given to studying the efficacy of SJW as a treatment for depression in the United States. Existing studies compare the efficacy of treatment with SJW to standard pharmacological treatments for depression and/or placebo. These studies have had mixed results. Although studies conducted in the 1990s have been criticized for having methodological flaws (Volz, 1997) , better designed studies still show mixed results. Studies of SJW treatment that show efficacy tend to make a distinction between mild, moderate, and severe cases of depression (Linde, Berner, Egger, & Mulrow, 2005) . The focus of this article will be to review and synthesize findings regarding the efficacy of SJW in the treatment of mild to moderate cases of major depressive disorder.
RESEARCH QUESTIONS
1. Is there sufficient evidence to warrant the use of SJW in the treatment of mild to moderate cases of depression? 2. What are the demographics of the sample populations studied for treatment of mild to moderate cases of depression with SJW? 3. What other factors, such as SJW standardization, study country of origin, and investigator financial backing contribute to the varied clinical findings regarding the treatment efficacy of SJW for mild and moderate cases of depression?
CONCEPTUAL FRAMEWORK
The biopsychosocial model of medicine and psychiatry is used as a framework for this article. George Engel designed this model based on systems theory (Engel, 1977) . He believed that the present standard, the medical model, was an insufficient way to understand a human being because its focus is on the disease and not on the whole person. He felt that a better model would take into account the human being in his environment and in his individual psychic life to understand how the disease state influences the person and how the person influences the disease state (Engel, 1977) .
Engel's application of systems theory to his model resulted in a view of the individual and his pathology as being composed of many microcosmic systems as well as being a part of macrocosmic systems more complex than the individual. Thus, an individual is composed of organ systems, which are composed of tissue and cells, which consist of molecules, which in turn are systems of atoms that consist of subatomic particles. Individuals themselves are nested within relational networks of increasingly higher orders of organization, such as dyads, families, the larger community, the subculture and culture, the society-nation, and finally the biosphere (Engel, 1980) . The disease state being discussed in this article is depression. Because the etiology of this disorder is not fully understood and because of the fact that depression can present differently from one person to another, a theory that considers individuals in their entirety is useful for understanding their pathology and hypothesizing how best to treat it.
Antidepressant medication is used to treat the individual at the system level of molecules. It is hypothesized that the molecular changes in the brain that antidepressant medications affect help alleviate some of the symptoms of depression. When the symptoms of depression remit, the individual's perception of his depressed state changes, resulting in a mitigation of depressive symptoms that had previously affected other levels of the systemic hierarchy, such as irritability in family relations or the inability to concentrate on work productively (Engel, 1980) . This is the mechanism by which SJW is hypothesized to affect the individual in his depressed, hypofunctioning state.
LITERATURE REVIEW

Method of Action of SJW in Depression
Although SJW has long been used by herbalists to treat depression, its mechanism of action is not well understood. Recent developments in biochemical technology allowing for extraction and subsequent identification of the various chemical constituents of herbs has allowed scientists to hypothesize in more specific detail about SJW's possible active ingredients. It is believed that the active constituents of SJW with antidepressant effects are hyperforin and hypericin. Hyperforin has been shown to increase the amount of available extracellular serotonin, dopamine, and norepinephrine in the central nervous system (CNS) synapses (Mischoulon & Rosenbaum, 2002) . In addition, hyperforin increases the amount of the excitatory amino acid glutamate in the synaptic cleft (Kaehler, Sinner, Chatterjee, & Philippu, 1999) ; glutamate has been increasingly implicated for its role in unipolar depression (Paul & Skolnick, 2003) . Hypericin is thought to have an impact on the hypothalamic-pituitaryadrenal axis, resulting in a decrease in cortisol production (Mischoulon & Rosenbaum, 2002) . High cortisol levels are known to play a role in stress, depression, and anxiety (Nickel et al., 2000) . Hypericin is also thought to inhibit the reuptake of serotonin, dopamine, and norepinephrine in the synapse, which is the same mode of action of many of the newer pharmaceutical antidepressant medications. At high doses, hypericin is a monoamine oxidase inhibitor (MAOI) (Lawvere & Mahoney, 2005) , and as with the pharmaceutical class of MAOIs in general, caution is required when consuming foods containing tyramine because of hypertensive reactions.
SJW is an inducer of the P450 enzyme system CYP3A4 and can reduce plasma levels of pharmacological agents such as cyclosporine, indinavir, digoxin, theophylline, irinotican, amitriptyline, alpraxolam, methadone, and warfarin. It can also decrease the efficacy of oral contraceptives. Because SJW may increase levels of serotonin in the CNS, it should not be used with selective serotonin reuptake inhibitors (SSRIs; Bezchlibnyk-Butler & Jeffries, 2004) .
SJW and Pharmaceutical Antidepressant Side Effects
Both SJW and prescription antidepressant medications are known to have side effects (NCCAM, 2004) . Pharmaceutical antidepressants have side effects that tend to vary by class.
Tricyclic antidepressants tend to have the broadest side-effect profile. Cognitive, neurological, anticholinergic, cardiovascular, gastrointestinal, endocrine, and sexual side effects can be experienced. Tricyclic drugs have a low therapeutic margin. A lethal dose of a tricyclic drug is only 3 times the maximum therapeutic dose (Bezchlibnyk-Butler & Jeffries, 2004) .
MAOIs have some of the same side effects as the tricyclic drugs, but to a lesser degree. Side effects are seen in the CNS, cardiovascular, gastrointestinal, and endocrine systems. Anticholinergic side effects are also noted, such as dry mouth and blurred vision. The major adverse effect of MAOI drugs is the possibility of hypertensive crisis created when the drug is mixed with foods that are high in tyramine (e.g., wine and aged cheeses), which can result in death (Bezchlibnyk-Butler & Jeffries, 2004) .
SSRIs tend to have a smaller incidence of side effects than either of the two previously discussed types of antidepressants. Cognitive, neurological, gastrointestinal, cardiovascular, endocrine, and sexual side effects can be seen. SSRIs can also cause "serotonin syndrome," which can result from taking too much of the medication at once or combining it with other similar medications. This syndrome can lead to death if not quickly recognized (Bezchlibnyk-Butler & Jeffries, 2004) .
SJW has been reported to have side effect profiles that are more similar to placebo than any class of pharmaceutical antidepressants (Trautmann-Sponsel & Dienel, 2004) . Side effects include dry mouth, dizziness, diarrhea, nausea, increased sensitivity to sunlight, and fatigue. Low side-effect profiles are one reason why people choose to take SJW instead of pharmaceutical antidepressants (Wagner et al., 1999) . SJW has the potential for drug interactions because of its established effect on the P450 system as described above. It could precipitate serotonin syndrome by blocking serotonin reuptake and the MAO enzyme at the same time if taken with an SSRI.
Efficacy of SJW in Mild-Moderate Depression
Depressive disorders, as defined by both the Diagnostic and Statistical Manual of Mental Disorders (4th ed.) (DSM-IV-TR; American Psychiatric Association, 2000) and the International Classification of Disease (ICD-10) are categorized according to the degree of severity of the depressive episode. The classifications are mild, moderate, and severe. Most studies showing efficacy of SJW in the treatment of depression have samples of patients who are mildly to moderately depressed (Volz, 1997) . However, even in studies that specifically look at these patient populations, there is variation in the reported efficacy of SJW versus placebo or standard pharmaceutical treatments. The NCCAM Web site (http://nccam.nih.gov/) states that there is "some scientific evidence that St. John's Wort is useful for treating mild to moderate depression," and that recent studies suggest that SJW is of "no benefit in treating major depression of moderate severity" (NCCAM, 2002) . The evidence-based CAM Web site Natural Standard.com, which in association with the Harvard Medical School reviews and compiles information from studies in academic journals, states that there is enough conclusive data supporting the efficacy of SJW to rate it an "A". This indicates that there is "strong scientific evidence for this use" (NaturalStandard.com, 2005) .
METHODS
We gathered information from studies by using the academic databases Medline, PsychInfo, and CINAHL. Studies were found by searching multiple terms under four main topics: depression, St. John's Wort, side effects, and demographics. Terms used for depression included depression, major depression, mild depression, moderate depression, major depressive disorder, and MDD. The term severe depression was not used, as it was not the focus of this article. Terms used for St. John's Wort included St. John's Wort, SJW, and hypericum. Terms for demographics included demographics, income, socio-economics, class, race, ethnicity, Caucasian, White, Asian, African-American, Black, Hispanic, Latino, Latina, sex, gender, male, female, men, and women. Each term was entered into each of the databases separately and then combined.
The internet search engine "Google" was used to find Web sites with journal articles, news releases, definitions for terminology, and basic consumer information regarding SJW, depression, antidepressant pharmaceuticals, and side effects of antidepressant medications. Additional information was found by accessing studies listed as references in studies that had been found via the Internet and academic databases.
The inclusion criteria were as follows:
1. The participants in the study had to be designated as suffering from mild to moderate cases of major depressive disorder. Studies that include information on severely depressed participants could be used, so long as the study included moderate and mild depression and compiled data separately on each of the designated groups. In this case, the information specific to the severely depressed group was disregarded. 2. Studies had to be in English or French, or translated into English or French. 3. To maintain current relevance and limit overall scope, studies had to be published no earlier than 2000. 4. Studies had to be the original work of the author.
RESULTS
Of the 12 studies in this article, 10 reported some efficacy of SJW as compared with placebo and equal or greater efficacy than standard pharmaceutical treatments.
Demographics
Twelve original articles met all the above inclusion criteria. The participants were adults aged 18 and over in 10 studies. In the remaining two studies, the participants were children and adolescents from 6 to 17 years of age. Both pediatric studies had difficulty with subject compliance and dropouts.
The majority of participants in five studies were Caucasian women. Of the 10 studies on adults, 4 of the participant groups included at least twice as many women as men. Four studies were predominantly female, and the remaining two studies did not specify the breakdown of men and women. Of the 12 total studies, 5 differentiated race or ethnicity. No group trends based on race or ethnicity were reported in these studies.
Sample Sizes
Four studies had less than 100 participants. Three studies had 100 to 200 participants, and two studies had 200 to 300 participants. Three studies had sample sizes in the range of 301 to 400. The two studies showing no efficacy had sample sizes of 200 (Shelton et al., 2001) and 340 (Hypericum Depression Trial Study Group, 2002) . Of these two, the study with the larger sample size had a SJW, placebo, and sertraline group. The other had only placebo and SJW groups (see Table 1 ).
Study Methods
One study was 4 weeks in duration, four studies were 6 weeks, one was 7 weeks, and four were 8 weeks in duration. Two studies were 12 weeks long (Fava et al., 2005; Gastpar et al., 2005) .
Of the 12 studies, 9 used a "double dummy" technique, wherein the taste, sight, and smell of the treatment medications were matched to the placebo to ensure double-blinding.
Diagnostic Criteria and Rating Scales
Of the 10 studies on adults, 6 used the DSM-IV criteria for major depressive disorder to diagnose research participants with mild or moderate levels of depression (major depressive disorder is the medical diagnosis of depression, and mild, moderate, and severe are modifiers of the diagnosis). Two studies used the ICD-10 criteria for mild and moderate levels of depression for diagnosis. One used both the DSM-IV and the ICD-10 for diagnosis, and another used the modified Structured Clinical Interview for DSM-IV (SCID) to diagnose major depressive disorder. One study used the DSM-IV criteria for major depressive disorder alone, without criteria for mild and moderate modifiers. This study, along with the one using the SCID, excluded suicidal and chronically depressed patients and had similar criteria for baseline Hamilton Depression Scale (HAM-D) scores compared to the other studies, and was therefore included. Both pediatric studies used the DSM-IV for diagnosis.
The primary outcome measure in all 10 adult studies was the HAM-D. Most studies included other depression scales as secondary measures, including the Global Assessment of Functioning (GAF), Clinical Global Impressions Scale (CGI), Von Zersson's Depression Scale, Patient's global assessment scale, and Beck Depression Inventory (BDI). The two pediatric studies used several scales, the overlapping ones being the Montgomery-Asberg Depression Rating Scale (MADRS) and the CGI. The MADRS was used as the primary outcome measure (see Table 2 ).
Efficacy
Of the 12 studies 11 demonstrated clinically significant improvement on some or all of the outcome measures (all studies had p values of .05 or less) in the SJW treatment group; 9 of these studies showed efficacy in the immediate treatment of the depression, and 2 showed efficacy only on remission rates of the disorder. However, one study (Shelton et al., 2001) that initially reported significant positive results on remission rates (defined as p < .02) concluded after further statistical analysis that their results were not definitive and that the finding was "likely influenced by the low variability around estimates that are close to zero Woelk (2000) ≥18
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Yes DSM-IV not used HAM-D, CGI, PGI (i.e., the remission rates were very low)" (p. 1983). The authors wrote in the conclusion of their study that "St. John's wort was not effective for treatment of major depression" (p. 1978), and so, this study has been labeled in this article as a study that showed no effective response. Categorizing it this way leaves 10 studies that reported efficacy and 2 that demonstrated none. Both pediatric studies showed significant improvement in primary outcome measures (both at p < .01) and reported minimal side effects. Neither of the pediatric studies compared SJW with a placebo or a pharmaceutical antidepressant.
Source of Extracts and Dosing
Extracts of SJW used in the 12 studies include the following products, all manufactured by German-based phytopharmaceutical companies: WS 5572, LI 160, Ze 117, STW 3, and WS 5570.
Two of the studies using fluoxetine as a pharmaceutical comparison used a dose of 20 mg, once daily. The third fluoxetine study failed to state what dose was used (Schrader, 2000) . The dose ranges of Sertraline were 50 to 100mg. The study that used imipramine gave it at a standard dose of 75 mg per day (see Table 3 ).
Funding and Pharmaceutical Affiliations
Of the 12 studies, 11 disclosed their financial backing at either the beginning or the end of the original article. The 12th study did not clearly state who funded the research but did disclose that the research was affiliated with a German company that manufactures SJW Woelk (2000) 324 250 mg BID Ze 117 Germany Yes Schrader (2000) 240 250 mg BID Ze 117 Germany Yes supplements (Gastpar et al., 2005) . Three of the studies were funded exclusively by government grants. Of these three, one was funded by the German medical insurance system (Schrader, 2000) , one by the U.S. National Institute of Health (NIH; Simeon et al., 2005) , and the third by the U.S. NIMH and the NCCAM (Hypericum Depression Trial Study Group, 2002) . Eight studies were funded by pharmaceutical companies that manufactured either SJW supplements or competing products such as Prozac (fluoxetine), Zoloft (sertraline), or Tofranil (imipramine). Of these eight studies, all reported favorable outcomes for their financial backers. The 12th study that acknowledged an "affiliation" with a German company that manufactures SJW supplements found that SJW was efficacious. Only 2 of the 12 studies disclosed author financial affiliations (Hypericum Depression Trial Study Group, 2002; Shelton et al., 2001) . These were also disclosed at either the beginning or the end of the original article. Authors in the two studies disclosed financial affiliations with multiple pharmaceutical companies, including Pfizer, the manufacturers of Zoloft (Sertraline). Both these studies found SJW to be ineffective in the treatment of mild to moderate depression.
Of the three studies that were funded by government grants, two demonstrated SJW efficacy, and one showed none. The study showing no efficacy disclosed author affiliations with multiple pharmaceutical companies, including Pfizer (Hypericum Depression Trial Study Group, 2002) . The study funded by the German medical insurance system (Schrader, 2000) did not disclose author affiliations nor did the study funded by NIH (Simeon et al., 2005) .
Use of Placebo and Pharmaceutical Groups
All the studies using adult participants (a total of 10) were randomized, double-blind, controlled, experimentally designed trials; 4 of these 10 studies used only a pharmaceutical antidepressant group as a control group; 3 of the 10 used only a placebo group as a control group; 3 studies used both a placebo and a pharmaceutical control comparison group. One of these three studies showed equal, clinically significant efficacy of SJW and fluoxetine over the placebo (Bjerkenstedt et al., 2005) . The second showed no effect of SJW or sertraline over the placebo (Hypericum Depression Trial Study Group, 2002) . The third showed clinically significant efficacy for SJW over fluoxetine, but just a trend toward efficacy over the placebo (Fava et al., 2005) . In this study, fluoxetine was less effective in treating depression than the placebo. The two pediatric studies were single-group, quasiexperimental designs using neither a placebo group nor a pharmaceutical group (Findling et al., 2003; Simeon et al., 2005) .
DISCUSSION
Of the 12 studies in this review, 10 reported some efficacy of SJW over the placebo and equal or better efficacy compared with standard pharmaceuticals in the treatment of mild to moderate depression. Hence, it appears that there is sufficient evidence to warrant the use of SJW in mildly to moderately depressed patients.
Standardization of the extract of SJW continues to be a fundamental issue in studying the effects of the supplement. Many different extracts were used in the studies, and the concentrations of hyperforin and hypericin, believed to be the two main active ingredients, were not consistently reported. Lack of standardization and nondisclosure of active ingredient concentrations nullifies the usefulness of reporting dosage information because it is not clear that the same amount of active ingredient is being used from study to study. This makes it difficult for one study to replicate the findings of another study, which would strengthen research findings on the subject.
The efficacy of SJW across race and ethnicity has not been well studied. Few studies gathered this demographic information and those that did generally did not trend efficacy or adverse effects specific to race or ethnicity. Most research on SJW efficacy thus far has included predominantly Caucasians.
The majority of studies disclosing the gender of the research participants had more women than men. Although most of the studies reported this demographic information, the focus of the studies was not specific to gender, so the efficacy and adverse effects specific to gender were not reviewed. It appears that there are preliminary data to support the efficacy and safety of SJW in children and adolescents. However, there are very few studies that address children and adolescents, and the existing studies had very small sample sizes (below 100).
More studies are needed that have larger sample sizes and that include placebo and pharmaceutical control groups. Only three studies in this review used this design, and they had varying results. At this point in SJW research, there appears to be sufficient indication that some positive treatment effect exists, but most of the experimentally designed studies to date have had small sample sizes and either a placebo group or a standard pharmaceutical group, or no control group at all. Again, this makes it difficult to replicate findings from study to study.
An additional issue across studies on SJW has been the process of making the diagnosis of major depressive disorder with the modifiers of mild and moderate levels of the disorder in research participants. Not all the studies used the same criteria for diagnosis of the disorder and its modifiers. Many studies used the DSM-IV (more commonly used by American psychiatric practitioners) or the ICD-10 (more commonly used by European psychiatric practitioners), which have similar diagnostic criteria but are not the same manual. Additionally, some studies used neither resource for diagnosis but, instead, diagnosed patients using the HAM-D. This is a commonly used test for the diagnosis of depression but is somewhat different in design from the DSM-IV and the ICD-10. Therefore, it cannot be assured that the diagnostic criteria for major depressive disorder of mild or moderate severity was exactly the same in all studies, making it even more difficult to make strong conclusions about the results of existing research.
Finally, more government funding is needed for research. The only consistent finding across all the studies was that the outcome of the study had positive financial implications for either the financial backers of the study or some or all the researchers involved in the study, and sometimes both. The only study that did not disclose any financial relationship with pharmaceutical companies manufacturing traditional medications for depression or SJW supplements was funded by the German medical insurance system, and that study found that SJW was efficacious. However, the study did not disclose any information about researchers' financial interests.
SUGGESTIONS FOR FUTURE RESEARCH
1. Studies should report the concentrations of the active ingredients in their SJW samples. They should also ensure by some means that their extracts are standardized across the entire sample, especially in the United States, where the FDA does not regulate herbal supplements. 2. More studies with larger sample sizes need to be done to determine the efficacy and adverse effects of SJW on samples differentiated by gender, ethnicity, race, and age. 3. All future studies should have both placebo and pharmaceutical comparison groups because the results of the three studies with this design since 2000 have had such varied results. 4. Research funded and implemented by parties with no financial interest in the outcome is needed.
